BARD1 Life Sciences Ltd (ASX: BD1) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

BARD1 Life Sciences Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $101.59 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 91.93 million
Earnings per share -0.083
Dividend per share N/A
Year To Date Return 62.50%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

BARD1 Life Sciences Ltd (ASX: BD1)
Latest News

BD1 ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About BARD1 Life Sciences Ltd

BARD1 Life Sciences Ltd is an Australian life sciences company. It focuses on developing and commercializing non-invasive diagnostic tests for the early detection of cancer including ovarian, breast, lung, prostate, bladder, and pancreaticcancers. Geographically, it operates and derives revenue from Australia. The company pipeline portfolio includes hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody tests for early detection of ovarian, breast and lung cancers, and the research-stage EXO-NET exosome-based liquid biopsy pipeline.

BD1 Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
15 Oct 2021 $1.11 $0.00 0.00% 139,782 $1.10 $1.12 $1.08
14 Oct 2021 $1.10 $0.05 4.76% 62,407 $1.06 $1.10 $1.06
13 Oct 2021 $1.05 $0.00 0.00% 81,014 $1.07 $1.08 $1.03
12 Oct 2021 $1.06 $-0.06 -5.41% 187,962 $1.12 $1.14 $1.05
11 Oct 2021 $1.11 $0.01 0.91% 173,203 $1.10 $1.13 $1.09
08 Oct 2021 $1.10 $-0.05 -4.35% 108,139 $1.15 $1.15 $1.08
07 Oct 2021 $1.15 $0.06 5.50% 168,733 $1.08 $1.15 $1.07
06 Oct 2021 $1.09 $0.07 6.86% 543,131 $1.03 $1.10 $1.03
05 Oct 2021 $1.02 $-0.07 -6.42% 336,241 $1.06 $1.07 $1.00
04 Oct 2021 $1.09 $0.01 0.93% 201,025 $1.07 $1.10 $1.06
01 Oct 2021 $1.08 $-0.01 -0.92% 180,448 $1.10 $1.10 $1.05
30 Sep 2021 $1.09 $-0.02 -1.80% 199,491 $1.11 $1.14 $1.09
29 Sep 2021 $1.11 $-0.03 -2.63% 244,326 $1.12 $1.13 $1.09
28 Sep 2021 $1.14 $0.01 0.88% 130,951 $1.14 $1.14 $1.11
27 Sep 2021 $1.13 $-0.02 -1.74% 170,752 $1.15 $1.18 $1.13
24 Sep 2021 $1.15 $0.02 1.77% 265,008 $1.13 $1.15 $1.11
23 Sep 2021 $1.13 $-0.04 -3.42% 701,295 $1.19 $1.19 $1.13
22 Sep 2021 $1.17 $-0.06 -4.90% 212,168 $1.21 $1.21 $1.17
21 Sep 2021 $1.23 $0.02 1.65% 323,337 $1.19 $1.23 $1.11
20 Sep 2021 $1.21 $-0.12 -9.06% 552,915 $1.31 $1.31 $1.20
17 Sep 2021 $1.33 $-0.02 -1.49% 145,702 $1.35 $1.35 $1.30

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
24 Aug 2021 Philip (Phil) Powell Buy 19 $29,998
Participation in share purchase plan.
24 Aug 2021 Geoffrey Cumming Buy 19 $29,998
Participation in share purchase plan.
24 Aug 2021 Robert (Max) Johnston Buy 19 $29,998
Participation in share purchase plan. As per announcement on 27/08/2021
04 Dec 2020 Geoffrey Cumming Buy 9 $7,066
On-market trade. Avg price
02 Dec 2020 Robert (Max) Johnston Buy 30 $20,385
On-market trade. Avg price.
02 Dec 2020 Philip (Phil) Powell Buy 70 $48,762
On-market trade. Avg price

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mrs Pauline Anne Collinson Company Secretary Nov 2001
Mrs Collinson has worked for the Company for 23 years and has held the position of Company Secretary for 14 years. She is also the Company Secretary of Tanami Gold NL (ASX:TAM).

Professor Allan Cripps Non-Executive Director Jan 2020
Professor Cripps had near 20 years experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. Professor Cripps is a academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services delivery. From 2005 to 2016, Professor Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research professor at Griffith University, led the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. He has published over 300 peer reviewed scientific papers, presented at international scientific conferences, and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. Currently Professor Cripps is Independent Chair of the Children's Health Research Alliance Board. He was previously Non-Executive Director of Research Australia (2005 - 2012) and the Gold Coast Hospital and Health Services Board (2011 - 2017). Professor Cripps is a member of the Risk Committees.
Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a range of sectors including pharma, utilities, IT, financial services, food and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney and Los Angeles. He is also a Chairman of the Risk Committee.
Mr Geoffrey A. Cumming Non-Executive ChairmanNon-Executive Director Jul 2020
--
Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Previously his career also included senior roles with Diageo and Unilever in Australia, Africa and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had overseas experience during his career in businesses in both Western and Central Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Director of ProLife Foods NZ.
Dr Leearne Hinch Chief Executive Officer Nov 2016
-
Mr Tony Di Pietro Joint Company SecretaryChief Financial Officer Jul 2020
-
Leearne Hinch Chief Executive Officer
-
Carl Stubbings Chief Operations Officer
-
Peter French Chief Scientific Officer
-
Tony Di Pietro Joint Company SecretaryChief Financial Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 210,205,341 8.78%
The Trust Company Australia Limited <Mof A/C> 204,000,000 8.52%
Moggs Creek Pty Ltd <Moggs Creek Super Fund A/C> 130,790,000 5.46%
Dr Irmgard Irminger-Finger 123,600,000 5.16%
J P Morgan Nominees Australia Pty Limited 44,247,405 1.85%
Citicorp Nominees Pty Limited 42,749,162 1.79%
Traoj Pty Ltd <Traoj A/C> 36,087,995 1.51%
David Neate 33,157,719 1.38%
BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient Drp> 32,909,435 1.37%
Tony Walker 30,867,552 1.29%
Mr John Andrew Rodgers <John Rodgers Family A/C> 29,924,216 1.25%
Supergun Pty Ltd <Bricklanding Super Fund A/C> 23,294,046 0.97%
Ajava Holdings Pty Ltd 23,000,000 0.96%
Worldwise Enterprises Pty Ltd 16,705,954 0.70%
Nathan Ryan Wagner 16,558,112 0.69%
Barrie Ernest Laws & Merrilyn Frances Laws <B&M Laws Fund A/C> 15,600,000 0.65%
Lynne Marie Wilks 15,500,000 0.65%
Ifm Pty Limited <Ifm Super Fund A/C> 15,166,666 0.63%
Russell Kay Hancock 15,000,000 0.63%
Pelagyia Pty Ltd <Caprice Super Fund A/C> 13,840,000 0.58%

Profile

since

Note